{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:56:34Z","timestamp":1791140194513,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The combined blockade of the IL-6R\/STAT3 and the MAPK signaling pathways has been shown to inhibit bone marrow microenvironment (BMM)\u2013mediated survival of multiple myeloma (MM) cells. Here, we identify the molecular chaperones heat shock proteins (Hsp) 90\u03b1 and \u03b2 as target genes of both pathways. The siRNA-mediated knockdown of Hsp90 or treatment with the novel Hsp90 inhibitor 17-DMAG attenuated the levels of STAT3 and phospho-ERK and decreased the viability of MM cells. Although knockdown of Hsp90\u03b2\u2014unlike knockdown of Hsp90\u03b1\u2014was sufficient to induce apoptosis, this effect was strongly increased when both Hsp90s were targeted, indicating a cooperation of both. Given the importance of the BMM for drug resistance and MM-cell survival, apoptosis induced by Hsp90 inhibition was not mitigated in the presence of bone marrow stromal cells, osteoclasts, or endothelial cells. These observations suggest that a positive feedback loop consisting of Hsp90\u03b1\/\u03b2 and major signaling pathways supports the survival of MM cells. Finally, in situ overexpression of both Hsp90 proteins was observed in most MMs but not in monoclonal gammopathy of undetermined significance (MGUS) or in normal plasma cells. Our results underpin a role for Hsp90\u03b1 and \u03b2 in MM pathogenesis.<\/jats:p>","DOI":"10.1182\/blood-2006-05-024372","type":"journal-article","created":{"date-parts":[[2006,9,27]],"date-time":"2006-09-27T02:48:11Z","timestamp":1159325291000},"page":"720-728","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":124,"title":["STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90\u03b1 and \u03b2 in multiple myeloma cells, which critically contribute to tumor-cell survival"],"prefix":"10.1182","volume":"109","author":[{"given":"Manik","family":"Chatterjee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"},{"name":"Robert Ro\u0308ssle Cancer Clinic at the Max Delbru\u0308ck Center for Molecular Medicine, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"},{"name":"Robert Ro\u0308ssle Cancer Clinic at the Max Delbru\u0308ck Center for Molecular Medicine, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Stu\u0308hmer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindaugas","family":"Andrulis","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Wu\u0308rzburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Ungethu\u0308m","sequence":"additional","affiliation":[{"name":"Laboratory for Functional Genomics, Charite\u0301, University Medicine Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Ju\u0308rgen","family":"Kuban","sequence":"additional","affiliation":[{"name":"Laboratory for Functional Genomics, Charite\u0301, University Medicine Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Lorentz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Bommert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Topp","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Kra\u0308mer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Konrad","family":"Mu\u0308ller-Hermelink","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Wu\u0308rzburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Greiner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital of Wu\u0308rzburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology, University Hospital of Wu\u0308rzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2006,9,26]]},"reference":[{"key":"2019111715050662700_B1","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc2003; 78:21\u201333.","DOI":"10.4065\/78.1.21"},{"key":"2019111715050662700_B2","doi-asserted-by":"crossref","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med2005; 352:2487\u20132498.","DOI":"10.1056\/NEJMoa043445"},{"key":"2019111715050662700_B3","doi-asserted-by":"crossref","unstructured":"Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood2004; 104:607\u2013618.","DOI":"10.1182\/blood-2004-01-0037"},{"key":"2019111715050662700_B4","doi-asserted-by":"crossref","unstructured":"Kuehl WM and Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program2005;346\u2013352.","DOI":"10.1182\/asheducation-2005.1.346"},{"key":"2019111715050662700_B5","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Ho\u0308nemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6\/gp130\/STAT3 pathway. Blood2002; 100:3311\u20133318.","DOI":"10.1182\/blood-2002-01-0102"},{"key":"2019111715050662700_B6","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res2004; 64:2016\u20132023.","DOI":"10.1158\/0008-5472.CAN-03-1131"},{"key":"2019111715050662700_B7","doi-asserted-by":"crossref","unstructured":"Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood2004; 104:2484\u20132491.","DOI":"10.1182\/blood-2003-11-3839"},{"key":"2019111715050662700_B8","doi-asserted-by":"crossref","unstructured":"Pellegrino A, Ria R, Di Pietro G, et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol2005; 129:248\u2013256.","DOI":"10.1111\/j.1365-2141.2005.05443.x"},{"key":"2019111715050662700_B9","doi-asserted-by":"crossref","unstructured":"Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood1998; 91:3\u201321.","DOI":"10.1182\/blood.V91.1.3.3_3_21"},{"key":"2019111715050662700_B10","doi-asserted-by":"crossref","unstructured":"Lentzsch S, Chatterjee M, Gries M, et al. PI3-K\/AKT\/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia2004; 18:1883\u20131890.","DOI":"10.1038\/sj.leu.2403486"},{"key":"2019111715050662700_B11","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Stu\u0308hmer T, Herrmann P, Bommert K, Do\u0308rken B, Bargou RC. Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood2004; 104:3712\u20133721.","DOI":"10.1182\/blood-2004-04-1670"},{"key":"2019111715050662700_B12","doi-asserted-by":"crossref","unstructured":"Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical. applications. A comprehensive review. Pharmacol Ther1998; 79:129\u2013168.","DOI":"10.1016\/S0163-7258(98)00013-8"},{"key":"2019111715050662700_B13","doi-asserted-by":"crossref","unstructured":"Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett2004; 562:11\u201315.","DOI":"10.1016\/S0014-5793(04)00229-7"},{"key":"2019111715050662700_B14","doi-asserted-by":"crossref","unstructured":"Whitesell L and Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer2005; 5:761\u2013772.","DOI":"10.1038\/nrc1716"},{"key":"2019111715050662700_B15","doi-asserted-by":"crossref","unstructured":"Zhang H and Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med2004; 82:488\u2013499.","DOI":"10.1007\/s00109-004-0549-9"},{"key":"2019111715050662700_B16","doi-asserted-by":"crossref","unstructured":"Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett2004; 206:149\u2013157.","DOI":"10.1016\/j.canlet.2003.08.032"},{"key":"2019111715050662700_B17","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood2006; 107:1092\u20131100.","DOI":"10.1182\/blood-2005-03-1158"},{"key":"2019111715050662700_B18","unstructured":"Buckley KA, Chan BY, Fraser WD, Gallagher JA. Human osteoclast culture from peripheral blood monocytes: phenotypic characterization and quantitation of resorption. Methods Mol Med2005; 107:55\u201368."},{"key":"2019111715050662700_B19","doi-asserted-by":"crossref","unstructured":"Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood2003; 102:3340\u20133348.","DOI":"10.1182\/blood-2003-04-1338"},{"key":"2019111715050662700_B20","doi-asserted-by":"crossref","unstructured":"Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science2002; 296:550\u2013553.","DOI":"10.1126\/science.1068999"},{"key":"2019111715050662700_B21","doi-asserted-by":"crossref","unstructured":"Brighenti A, Andrulis M, Geissinger E, Roth S, Mu\u0308ller-Hermelink HK, Ru\u0308diger T. Extrafollicular proliferation of B cells in the absence of follicular hyperplasia: a distinct reaction pattern in lymph nodes correlated with primary or recall type responses. Histopathology2005; 47:90\u2013100.","DOI":"10.1111\/j.1365-2559.2005.02173.x"},{"key":"2019111715050662700_B22","doi-asserted-by":"crossref","unstructured":"Tian ZQ, Liu Y, Zhang D, et al. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem2004; 12:5317\u20135329.","DOI":"10.1016\/j.bmc.2004.07.053"},{"key":"2019111715050662700_B23","doi-asserted-by":"crossref","unstructured":"Stephanou A, Conroy S, Isenberg DA, et al. Elevation of IL-6 in transgenic mice results in increased levels of the 90 kDa heat shock protein (hsp90) and the production of anti-hsp90 antibodies. J Autoimmun1998; 11:249\u2013253.","DOI":"10.1006\/jaut.1998.0194"},{"issue":"pt 1","key":"2019111715050662700_B24","first-page":"103","volume":"321","year":"1997","journal-title":"Biochem J"},{"issue":"pt 1","key":"2019111715050662700_B25","first-page":"189","volume":"330","year":"1998","journal-title":"Biochem J"},{"key":"2019111715050662700_B26","doi-asserted-by":"crossref","unstructured":"Kalvakolanu DV and Roy SK. CCAAT\/enhancer binding proteins and interferon signaling pathways. J Interferon Cytokine Res2005; 25:757\u2013769.","DOI":"10.1089\/jir.2005.25.757"},{"key":"2019111715050662700_B27","doi-asserted-by":"crossref","unstructured":"Shang L and Tomasi TB. The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J Biol Chem2006; 281:1876\u20131884.","DOI":"10.1074\/jbc.M509901200"},{"key":"2019111715050662700_B28","doi-asserted-by":"crossref","unstructured":"Sato N, Yamamoto T, Sekine Y, et al. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem Biophys Res Commun2003; 300:847\u2013852.","DOI":"10.1016\/S0006-291X(02)02941-8"},{"key":"2019111715050662700_B29","doi-asserted-by":"crossref","unstructured":"Schulte TW, Blagosklonny MV, Romanova L, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol1996; 16:5839\u20135845.","DOI":"10.1128\/MCB.16.10.5839"},{"key":"2019111715050662700_B30","doi-asserted-by":"crossref","unstructured":"Jaiswal RK, Weissinger E, Kolch W, Landreth GE. Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J Biol Chem1996; 271:23626\u201323629.","DOI":"10.1074\/jbc.271.39.23626"},{"key":"2019111715050662700_B31","unstructured":"Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase\/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res2000; 60:6763\u20136770."},{"key":"2019111715050662700_B32","doi-asserted-by":"crossref","unstructured":"Valbuena JR, Rassidakis GZ, Lin P, et al. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol2005; 18:1343\u20131349.","DOI":"10.1038\/modpathol.3800459"},{"key":"2019111715050662700_B33","doi-asserted-by":"crossref","unstructured":"Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res2006; 12:584\u2013590.","DOI":"10.1158\/1078-0432.CCR-05-1194"},{"key":"2019111715050662700_B34","doi-asserted-by":"crossref","unstructured":"Cohen-Saidon C, Carmi I, Keren A, Razin E. Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90beta. Blood2006; 107:1413\u20131420.","DOI":"10.1182\/blood-2005-07-2648"},{"key":"2019111715050662700_B35","doi-asserted-by":"crossref","unstructured":"Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol2005; 56:126\u2013137.","DOI":"10.1007\/s00280-004-0947-2"},{"key":"2019111715050662700_B36","doi-asserted-by":"crossref","unstructured":"Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol2002; 49:7\u201319.","DOI":"10.1007\/s00280-001-0380-8"},{"key":"2019111715050662700_B37","doi-asserted-by":"crossref","unstructured":"Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood2004; 104:1825\u20131832.","DOI":"10.1182\/blood-2003-12-4218"},{"key":"2019111715050662700_B38","doi-asserted-by":"crossref","unstructured":"Vacca A and Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia2006; 20:193\u2013199.","DOI":"10.1038\/sj.leu.2404067"},{"key":"2019111715050662700_B39","doi-asserted-by":"crossref","unstructured":"Eiseman JL, Lan J, Lagattuta TF, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol2005; 55:21\u201332.","DOI":"10.1007\/s00280-004-0865-3"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/2\/720\/1285015\/zh800207000720.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/2\/720\/1285015\/zh800207000720.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T20:05:28Z","timestamp":1574021128000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/109\/2\/720\/23519\/STAT3-and-MAPK-signaling-maintain-overexpression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,26]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,9,26]]},"published-print":{"date-parts":[[2007,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-05-024372","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,26]]}}}